BlossomHill's BH-30643 Offers New Hope for Resistant Lung Cancer

SAN DIEGO, CA – September 15, 2026 – In a significant development for oncology, BlossomHill Therapeutics has unveiled promising data for its investigational drug, BH-30643, offering a potential breakthrough for a notoriously difficult-to-treat group of non-small cell lung cancer (NSCLC) patients. The updated results from the ongoing Phase 1/2 SOLARA trial, presented at the prestigious IASLC 2026 World Conference on Lung Cancer in Seoul, demonstrate substantial anti-tumor activity against cancers harboring the EGFR C797S resistance mutation—a group for which no targeted therapies are currently approved.

The San Diego-based biopharmaceutical company reported that in a cohort of 40 heavily pretreated patients, BH-30643 achieved a 45% objective response rate (ORR), meaning tumors significantly shrank in nearly half of the participants. Furthermore, the drug demonstrated an 88% disease control rate (DCR), indicating that it halted tumor growth or shrank tumors in the vast majority of patients. This clinical milestone not only offers a beacon of hope for patients who have exhausted other options but also marks a pivotal strategic step for a company aiming to redefine cancer treatment through intentional chemical design.

The Evolving Battle Against EGFR-Mutant Lung Cancer

For over a decade, the treatment of NSCLC with epidermal growth factor receptor (EGFR) mutations has been a story of remarkable progress followed by frustrating setbacks. Targeted therapies known as EGFR inhibitors transformed the prognosis for many patients, replacing grueling chemotherapy with a daily pill that could hold the disease at bay. However, cancer's relentless adaptability means that resistance is an inevitable challenge.

Third-generation inhibitors, such as osimertinib, were a major leap forward, effectively targeting the T790M resistance mutation that thwarted earlier drugs. Yet, as physicians and patients know all too well, this victory is often temporary. Over time, many tumors develop a new line of defense: the C797S mutation. This specific alteration changes the structure of the EGFR protein in a way that prevents drugs like osimertinib from binding, rendering them ineffective. For patients whose tumors develop this mutation, the path forward becomes uncertain, often leading back to traditional chemotherapy with its more severe side effects and limited efficacy.

“C797S-driven resistance to third-generation EGFR inhibitors was first described over 10 years ago, yet patients whose tumors develop this mutation currently have no approved targeted treatment options,” said Hidehito Horinouchi, M.D., Ph.D., of the National Cancer Center Hospital in Tokyo, and the study's presenting author. The lack of effective treatments for this growing patient population represents one of the most significant unmet needs in modern thoracic oncology.

A Breakthrough in Targeted Therapy Design

BlossomHill’s BH-30643 was engineered specifically to outsmart this resistance mechanism. Described as a non-covalent, OMNI-EGFR™ inhibitor, its design circumvents the binding problem that stymies earlier drugs. The encouraging results from the SOLARA trial provide the first major clinical validation of this innovative approach.

The 45% response rate is particularly compelling given the patient population. These individuals were heavily pretreated, with a median of two prior lines of therapy. Nearly all (98%) had previously received osimertinib, and over half had also undergone chemotherapy or treatment with an antibody-drug conjugate. The durability of the response is also notable; at the time of the data analysis, 63% of patients remained on treatment, with a median follow-up of 6.9 months, suggesting a lasting benefit.

Equally crucial for any new therapy is its safety profile. A drug's effectiveness is often weighed against its tolerability. Here, BH-30643 also appears to shine. Treatment-related dose reductions and discontinuations were low, occurring in just 9% and 3% of patients, respectively. Most side effects typically associated with EGFR inhibition were mild. This favorable safety profile suggests that patients may be able to stay on the treatment longer, maximizing its potential benefit.

“These updated results provide important clinical validation of the approach we took in intentionally designing BH-30643 to address on-target EGFR resistance, including C797S,” commented Geoff Oxnard, M.D., Chief Medical Officer of BlossomHill Therapeutics. “We are encouraged to see meaningful anti-tumor activity across a molecularly diverse group of patients... with a favorable safety profile.”

Navigating the Path to Market

The positive data is amplified by a recent strategic win for the company: the receipt of FDA Fast Track designation for BH-30643. This designation is intended to expedite the development and review of drugs that treat serious conditions and fill an unmet medical need. It allows for more frequent communication with the FDA and opens the door for a potentially accelerated approval process, a significant advantage in the highly competitive oncology market.

While BlossomHill appears to be a frontrunner, it is not alone. The C797S mutation is a prime target for several biotech firms developing so-called “fourth-generation” EGFR inhibitors. Success will depend not only on superior efficacy but also on safety, durability, and the ability to navigate the complex global regulatory landscape. The strong early data on all these fronts gives BlossomHill a formidable position.

This strategic momentum is critical as the company looks ahead. The announcement solidifies its position as a serious contender in the oncology space, validating the scientific platform pioneered by its founder and industry veteran, J. Jean Cui, Ph.D., whose track record includes contributions to three previously FDA-approved cancer drugs. This pedigree lends substantial credibility to the company's ambitious goals.

BlossomHill is now preparing for its next major strategic move: the initiation of a global Phase 2 study targeting EGFR C797S-positive NSCLC, planned for the first quarter of 2027. This next phase will be crucial in confirming the drug's efficacy in a larger population and moving it one step closer to becoming a new standard of care for patients who are currently out of options.